The quiet biotech company in the big Mission Bay building is ready to make some noise.
FibroGen Inc., the largest biotech employer in San Francisco’s life sciences neighborhood, could get some answers early next year from clinical trials in anemia and pancreatic cancer while it starts Phase II trials in China for a chronic kidney disease-related anemia treatment.
Positive studies would vault FibroGen’s profile after years of the company quietly plugging away at its scientific business. What’s more, strong data could push the 250-employee company to go on a hiring binge and exercise an April 2011 option on an adjacent 211,000-square-foot building.
FibroGen Inc., the largest biotech employer in San Francisco’s life sciences neighborhood, could get some answers early next year from clinical trials in anemia and pancreatic cancer while it starts Phase II trials in China for a chronic kidney disease-related anemia treatment.
No comments:
Post a Comment